Answers are grounded in this paper and cite their sources.
Toll-like receptor (TLR) signaling contributes to inflammatory activation during autoimmune neuroinflammation. We previously demonstrated that a cell-penetrating TLR inhibitory peptide (cpTLR-i), designed to interfere with TLR adaptor recruitment, alleviated experimental colitis through functional modulation of macrophages. Here, we investigated the therapeutic and immunomodulatory effects of cpTLR-i in experimental autoimmune encephalomyelitis (EAE). cpTLR-i suppressed inflammatory mediator production in activated BV2 microglia while preserving MHC class II expression. Systemic cpTLR-i treatment delayed EAE onset, reduced disease severity, and attenuated CNS inflammation and demyelination. Immune profiling revealed reduced granulocyte accumulation and type 1 CD4+ T cells, increased FoxP3+ regulatory T cells, and functional reprogramming of microglia and infiltrating macrophages. Notably, cpTLR-i enhanced apoptotic-cell uptake by microglia and macrophages in vitro and induced an efferocytosis-associated program characterized by increased LXRα and CD36 expression even in the absence of exogenous TLR ligands. Pharmacological inhibition further implicated LXR signaling in this response, while cpTLR-i altered SOCS/STAT3 signaling, revealing an unexpected association between modulation of TLR signaling and signaling networks involved in the regulation of efferocytosis. These findings demonstrate that cpTLR-i not only suppresses inflammatory responses but also promotes pro-resolving functions of microglia and macrophages, suggesting that selective modulation of TLR signaling represents a potential therapeutic strategy for neuroinflammatory diseases.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: